β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer.
Fiche publication
Date publication
janvier 2015
Journal
Frontiers in pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DONTENWILL Monique, Pr LEHMANN Maxime, Dr MARTIN Sophie
Tous les auteurs :
Blandin AF, Renner G, Lehmann M, Lelong-Rebel I, Martin S, Dontenwill M
Lien Pubmed
Résumé
Integrins belong to a large family of αβ heterodimeric transmembrane proteins first recognized as adhesion molecules that bind to dedicated elements of the extracellular matrix and also to other surrounding cells. As important sensors of the cell microenvironment, they regulate numerous signaling pathways in response to structural variations of the extracellular matrix. Biochemical and biomechanical cues provided by this matrix and transmitted to cells via integrins are critically modified in tumoral settings. Integrins repertoire are subjected to expression level modifications, in tumor cells, and in surrounding cancer-associated cells, implicated in tumor initiation and progression as well. As critical players in numerous cancer hallmarks, defined by Hanahan and Weinberg (2011), integrins represent pertinent therapeutic targets. We will briefly summarize here our current knowledge about integrin implications in those different hallmarks focusing primarily on β1 integrins.
Mots clés
angiogenesis, hallmarks of cancer, integrins, migrationinvasion, proliferation, resistance to cell death, therapeutic target
Référence
Front Pharmacol. 2015 ;6:279